000070621 001__ 70621 000070621 005__ 20200221144347.0 000070621 0247_ $$2doi$$a10.3389/fchem.2015.00071 000070621 0248_ $$2sideral$$a106077 000070621 037__ $$aART-2016-106077 000070621 041__ $$aeng 000070621 100__ $$aConde, J. 000070621 245__ $$aEditorial: Cancer Nanotheranostics: What Have We Learned So Far? 000070621 260__ $$c2016 000070621 5060_ $$aAccess copy available to the general public$$fUnrestricted 000070621 5203_ $$aAccording to the National Cancer Institute, in 2015 an estimated of 1.7 million new cases of cancer will be diagnosed only in the United States and around 600, 000 people will die from the disease. The most common type of cancer is breast cancer, with more than 234, 000 new cases expected in the United States in 2015. The next most common cancers are prostate cancer and lung cancer.After a quarter of century of rapid technological advances, research has revealed the complexity of cancer, a disease intimately related to the dynamic transformation of the genome. These transformations trigger a range of modification to cell processes and molecular events that initiate and promote tumor genesis and progression, then local invasion and metastasis, i.e., the hallmarks of cancer development. These alterations may cause a wide scope of “diseases” that share similar molecular patterns that cause transformation and malignancy. Each of this stepwise evolution of the initial molecular event drives abnormal growth and loss of differentiation that ultimately causes tissue and organ failure. The initial molecular event may lay within the erroneous expression of a given gene, epigenetic modification and/or sporadic mutations occurring on genomic DNA during the life span of organisms. Each and every one of these molecular events may be evaluated and used as diagnostics biomarker and therapeutic target. For example, therapy action may target a mutated gene and silence its expression so as to avoid erroneous protein expression that mutates cell function. However, the full understanding of the molecular onset of this disease is still far from achieved and the search for mechanisms of treatment will follow closely... 000070621 536__ $$9info:eu-repo/grantAgreement/EC/FP7/626386/EU/Hydrogel-nanoparticle patches as prophylactic scaffold agents for in vivo local gene/drug delivery in colorectal cancer tumours/CANCERHYDROGELPATCH 000070621 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000070621 590__ $$a3.994$$b2016 000070621 591__ $$aCHEMISTRY, MULTIDISCIPLINARY$$b44 / 166 = 0.265$$c2016$$dQ2$$eT1 000070621 592__ $$a0.963$$b2016 000070621 593__ $$aChemistry (miscellaneous)$$c2016$$dQ1 000070621 655_4 $$ainfo:eu-repo/semantics/other$$vinfo:eu-repo/semantics/publishedVersion 000070621 700__ $$aTian, F.R. 000070621 700__ $$0(orcid)0000-0003-1081-8482$$ade la Fuente, J.M.$$uUniversidad de Zaragoza 000070621 700__ $$aBaptista, P.V. 000070621 700__ $$aBaptista, P. 000070621 7102_ $$12013$$2765$$aUniversidad de Zaragoza$$bDpto. Química Orgánica$$cÁrea Química Orgánica 000070621 773__ $$g3 (2016), 71 [3 pp]$$pFront. chem.$$tFrontiers in chemistry$$x2296-2646 000070621 8564_ $$s198421$$uhttps://zaguan.unizar.es/record/70621/files/texto_completo.pdf$$yVersión publicada 000070621 8564_ $$s103457$$uhttps://zaguan.unizar.es/record/70621/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000070621 909CO $$ooai:zaguan.unizar.es:70621$$particulos$$pdriver 000070621 951__ $$a2020-02-21-13:53:00 000070621 980__ $$aARTICLE